Mesoblast disappoints in another below-the-range biotech IPO

Damian Garde

Australian priced its U.S. IPO below expectations, raising $ 60 million to support its pipeline of cell therapies.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS